Ebola virus disease and HAT treatment centers spatial distribution.

<p>This figure shows the spatial distribution of Ebola virus disease (EVD) incidence with both EVD and Human African Trypanosomiasis (HAT) treatment centers and newly diagnosed HAT cases during the study period (before and during Ebola outbreak) in coastal Guinea. *HAT: Human African Trypanosomiasis. ¥ Before Ebola: from Feb.2012 to Dec.2013. § During Ebola: from Jan.2014 to Oct.2015.</p

Timeline of the Ebola epidemic and HAT control activities.

<p>This figure shows in parallel the main events of the Ebola epidemic and of Human African Trypanosomiasis (HAT) control activities between October 2013 and April 2016.</p

Impact of Ebola outbreak on HAT testing and caring activities in Guinea, January 2012 to October 2015.

<p>This panel figure displays: (A) Monthly evolution of the number of persons diagnosed during active campaigns by HAT treatment center; (B) Monthly evolution of the number of persons tested passively by HAT treatment center (and as from 2014 corresponding district); (C) Monthly evolution of the number of persons initiating therapy by HAT treatment center; (D) Monthly evolution of the number of persons initiating HAT therapy according to the type of screening; (E) Monthly evolution of the number of persons initiating HAT therapy by disease stage at diagnosis (F) Monthly evolution of the number of persons attending 3 months post-treatment follow-up visit. HAT: Human African Trypanosomiasis: *Passive routine testing data were available only between January 2014 and October 2015. **All post-treatment follow-up visits were centralized at the Dubreka center whatever the place where the patients received HAT therapy (Dubreka, Boffa or Forecariah HAT centers).</p

Passive screening and patients treated for HAT

Passive screening database, HAT treated patients database, thesaurus, data used for the article figures 3A to 3F

Cytokine levels measured in the CSF and plasma of HAT patients according to the disease stage.

1<p>Interquartile range.</p>2<p>P values are given for the three class comparisons (stage1, early stage 2, and late stage 2), p-values<0.05 are in bold.</p><p>Cytokine levels measured in the CSF and plasma of HAT patients according to the disease stage.</p

Cytokine profiles and infection outcomes in gambiense HAT.

<p>Cytokine profiles and infection outcomes in gambiense HAT.</p

Prognostic value of cytokine levels in SERO TL+.

<p>The prognostic value of cytokine levels measured at inclusion was evaluated by stepwise multivariate logistic regression analysis. For this, SERO TL+ individuals were spited into three categories according to follow-up results: those who were confirmed as HAT patients (SERO TL+/HAT; n = 12; G1), those who presented decreasing CATT responses (SERO TL+/CATTneg; n = 15; G2) and those who maintained high CATT responses and remained negative in parasitology (SERO TL+/CATT≥1/8; n = 13; G3). Three models were then constructed independently by a stepwise procedure comparing SERO TL+/HAT (model I), SERO TL+/CATTneg (model II) and SERO TL+/CATT≥1/8 (model III) to the two other groups.</p>1<p>The covariate univariate p-value before the stepwise procedure is shown in between brackets.</p>2<p>Cytokine levels were assigned to two class of equal size using the cytokine median value as the threshold.</p>3<p>Odds ratio.</p>4<p>Confidence interval.</p><p>Prognostic value of cytokine levels in SERO TL+.</p

Principal component analysis of cytokine responses in HAT patients and SERO TL+.

<p>A. Histogram of eigenvalues. The eigenvalues, which corresponds to the amount of variance accounted by each component, are presented for the first ten components. The two first components, which explain more than 50% of the total variance, are in black. B. First factorial plan (x-axis: first component, y-axis: second component). The plan composed by the two first axis or dimensions is represented. It corresponds to an approximation of the cloud of points by a 2-dimensional space. C. Absolute contribution of each cytokine to the variance of the second component.</p

Plasmatic cytokine profiles in HAT patients, SERO TL+ subjects, and endemic controls.

<p>Box plots of cytokine concentration are presented. Boxes represent the medians and interquartile ranges and whiskers represent 10^th and 90^th percentiles. Asterisks indicate significant differences over the control group: ****, p<0.0001; ***, p<0.001; **, p<0.01; *, p<0.05 (nonparametric Wilcoxon signed-rank test). Only cytokines with significant differences are shown. Group effectives: control (n = 40); HAT (n = 52); SERO TL+ (n = 60).</p

Phenotypic and demographic characteristics of the study sample.

<p>Phenotypic and demographic characteristics of the study sample.</p